Lb Pharmaceuticals (LBRX) Operating Expenses (2024 - 2026)

Lb Pharmaceuticals' Operating Expenses history runs 3 years deep, the most recent figure standing at $22.1 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 243.82% year-over-year to $22.1 million in Q1 2026; TTM through Mar 2026 was $47.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $30.4 million, down 53.1% from the prior year.
• Operating Expenses improved to $22.1 million in Q1 2026 per LBRX's latest filing, from $13.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $22.1 million in Q1 2026 and bottomed at $5.2 million in Q3 2025.
• The 3-year median for Operating Expenses is $10.1 million (2025), against an average of $11.5 million.
• Across the five-year window, Operating Expenses plunged 67.38% in 2025 and soared 243.82% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $5.5 million in 2024, then jumped by 150.41% to $13.9 million in 2025, then jumped by 59.37% to $22.1 million in 2026.
• Per Business Quant, the three latest LBRX Operating Expenses figures stand at $22.1 million (Q1 2026), $13.9 million (Q4 2025), and $5.2 million (Q3 2025).